NDAORALTABLET
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPRESSOR HCT is a fixed-dose oral combination tablet containing metoprolol tartrate (beta-blocker) and hydrochlorothiazide (thiazide diuretic). It treats hypertension by reducing blood pressure through dual mechanisms: beta-adrenergic blockade and diuretic action. This combination product targets patients requiring both agents for optimal cardiovascular control.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely in maintenance or transition mode, potentially smaller than peak-lifecycle teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LOPRESSOR HCT has zero linked job openings, reflecting its mature lifecycle and approaching LOE status. Career opportunities on this product are typically maintenance-focused roles in sales, market access, and regulatory support rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on LOPRESSOR HCT at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.